Publications library

Publications

Therapeutic Areas

Modeling & Meta-Analyses

Newest to Oldest

Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective

Authors: N Dhanji, T Cristina Decimoni, M T D Dyer , J R May, G van de Wetering, S Petersohn, K Nickel, A Silva, D Q B Muniz, A P C D Oliveira

Cost-Effectiveness of pneumococcal vaccination in adults in Italy: comparing new alternatives and exploring the role of GMT ratios in informing vaccine effectiveness

Authors: V Restivo, V Baldo, L Sticchi, F Senese, G M Prandi, L Pronk, K Owusu-Edusei, K D Johnson, T Ignacio

Budget impact analysis of a digital monitoring platform for COPD

Authors: T J Inocencio, K L Sterling, S Sayiner, M E Minshall, L Kaye, U Hatipoğlu

Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma

Authors: S Petersohn, B McGregor, SL Klijn, JR May, F Ejzykowicz, M Kurt, M Dyer, B Malcolm, S Branchoux, K Nickel, S George, S Kroep

Modeling monthly migraine-day distributions using longitudinal regression models and linking quality of life to inform cost-effectiveness analysis: A case study of Fremanezumab in Japanese-Korean migraine patients

Authors: X Wang, K Yamato, Y Kojima, J J Paris, E F P Peterse, M J H G Simons & C Bennison

An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1

Authors: L A Evitt, S Nanji, R A Grove, C Okoli, J van Wyk, S Snedecor

Cost-effectiveness of Nivolumab plus Ipilimumab for the first-line treatment of intermediate/poor-risk advanced and/or metastatic renal cell carcinoma in Switzerland

Authors: E Çakar, C Oniangue-Ndza, R P Schneider, S L Klijn, U M Vogl, C Rothermundt, J R May

A probabilistic cost-effectiveness analysis of Venetoclax and Obinutuzumab as a first-line therapy in chronic lymphocytic leukemia in Canada

Authors: A Chatterjee, G van de Wetering, R Goeree, C Owen, A M Desbois, S Barakat, B S Manzoor, K Sail

Cost and clinical benefits associated with Oncotype DX® test in patients with early-stage HR+/HER2- node-negative breast cancer in the Netherlands

Authors: F E de Jongh, R Efe, K H Herrmann, J A Spoorendonk

48-Week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-Infected patients: A systematic review and network meta-analysis

Authors: D A Patel, S J Snedecor, W Yu Tang, L Sudharshan, J W Lim, R Cuffe, S Pulgar, K A Gilchrist, R Refoios Camejo, J Stephens, G Nichols

View older